Overview

A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer

Status:
RECRUITING
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of carbognilumab combined with chemotherapy as the first-line treatment for patients with STK11 mutated advanced or postoperative recurrent non-small cell lung cancer (NSCLC).
Phase:
PHASE2
Details
Lead Sponsor:
Guangzhou Institute of Respiratory Disease